ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » AMGN Stock Price » AMGN Stock News

Amgen Inc. Share News

 Amgen Inc. (mm) Stock Price
AMGN Stock Price
 Amgen Inc. (mm) Stock Chart
AMGN Stock Chart
 Amgen Inc. (mm) Stock News
AMGN Stock News
 Amgen Inc. (mm) Company Information
AMGN Company Information
 Amgen Inc. (mm) Stock Trades
AMGN Stock Trades

Amgen: 84% Of Micromet Shares Have Been Tendered

DOW JONES NEWSWIRES Amgen Inc. (AMGN) said nearly 84% of the shares of biotechnology company Micromet Inc. (MITI) have been tendered to its $1.16 billion takeover offer, meeting all the conditions for the acquisition to close. As of the offering's expiration Thursday, about 80 million Micromet shares had been tendered and not withdrawn. An added 3.15 million shares have been tendered by guaranteed delivery. A subsequent offering period is scheduled to expire at 12:00 a.m. EST, at the end of March 6. Amgen launched its bid to acquire Micromet in January with an aim to strengthen Amgen's cancer-drug research pipeline. A Delaware judge declined to block Amgen's purchase of Micromet, the Associated Press reported Thursday. A group of Micromet shareholders had argued that Micromet didn't try hard enough to get a better offer, and sought a preliminary injunction. The judge found that the shareholders didn't show a reasonable likelihood that they would successfully prove their claims, the AP reported. Amgen shares closed at $67.59 Thursday and were inactive premarket. The stock is up 32% in the past 12 months. -By Nathalie Tadena, Dow Jones Newswires; 212-416-3287; nathalie.tadena@dowjones.com

Stock News for Amgen Inc. (AMGN)
DateTimeHeadline
07/31/201510:00:12U.S. Hot Stocks: Hot Stocks to Watch
07/31/201509:44:26U.S. Hot Stocks: Hot Stocks to Watch
07/30/201519:05:00Initial Statement of Beneficial Ownership (3)
07/30/201518:07:11Amgen Raises 2015 Outlook, Results Beat Expectations -- 2nd Update
07/30/201516:50:18Amgen Raises 2015 Outlook, Results Beat Expectations
07/30/201516:43:25Amgen Raises 2015 Outlook, Results Beat Expectations -- Update
07/30/201516:33:30Amgen Raises 2015 Outlook, Results Beat Expectations
07/30/201516:21:01Current Report Filing (8-k)
07/30/201516:05:00Amgen Announces Appointment Of Fred Hassan To Board Of Directors
07/30/201516:01:00Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4...
07/28/201517:46:00Amgen Announces 2015 Third Quarter Dividend
07/28/201512:26:16Merck Earnings Hurt by Arthritis Drug Knockoffs
07/27/201516:01:00Amgen Announces Webcast of 2015 Second Quarter Financial Results
07/24/201515:21:49Correction to Amgen/Kyprolis Article
07/24/201515:00:06FDA Approves Cholesterol Drug From Regeneron, Sanofi
07/24/201513:30:24FDA Approves Amgen's Kyprolis for Earlier Myeloma Treatment
07/24/201513:25:56FDA Approves Amgen's Kyprolis As a Second-Line Multiple Myeloma...
07/24/201512:40:00FDA Approves Kyprolis® (carfilzomib) For Combination Use In...
07/24/201509:10:04AbbVie's Revenue Growth Misses Expectations
07/24/201508:57:08AbbVie's Revenue Growth Misses Expectations

Amgen Inc. and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad